Aster DM Healthcare Limited — Credit Ratings, 10-12-2024: Credit Rating- Revision

Aster DM Healthcare Limited reported consolidated operating income of ₹3,698.9 crore, reflecting a growth of 20.5% year-over-year. This growth can be attributed to increased demand and an expanded operational footprint in India's healthcare sector.

The company's net profit for the period stood at ₹222.9 crore, compared to ₹185.4 crore in the previous fiscal year, resulting in an earnings per share (EPS) of ₹5.36. Improved operational efficiencies and a focus on enhancing service capabilities have positively impacted profitability.

Operational costs have risen, with a total outside liabilities to tangible net worth ratio increasing to 2.8 times, indicating potential concerns over leverage. However, the interest coverage ratio remained robust at 4.9 times, suggesting adequate capacity to service debt.

The latest credit rating action saw ICRA placing the company's ratings under a watch with positive implications for its total credit facilities of ₹602 crore, mainly driven by the anticipated benefits from the upcoming merger with Quality Care India Limited. The merger is projected to enhance Aster’s operational scale, creating an entity with around 38 hospitals and greater market presence.

The strategic outlook appears optimistic, with the merger expected to unlock synergies and improve market positioning. Given the positive revenue trajectory, operational improvements, and strategic maneuvers, there is a favorable sentiment toward the stock. Investors may consider a buy stance, monitoring how effectively the company leverages its increased scale and manages operational challenges post-merger.